PULMONARY DELIVERY OF MRI-1867 (ZEVAQUENABANT) AS AN EFFECTIVE THERAPEUTIC MODALITY IN PULMONARY FIBROSIS
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1140217 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Pulmonary fibrosis (PF) is a life-threatening disease in need of effective and well-tolerated therapeutic modalities. Previously, the distinct pathogenic roles of cannabinoid receptor 1 (CB1R) and iNOS activation in lungs were highlighted in PF to improve efficacy by dual-target therapy. However, cell-specific role of CB1R in PF has not been explored. Here, we demonstrated that CB1R in alveolar macrophages (AMs) is responsible to release anandamide into alveoli and promote PF. Activation of CB1R in AMs orchestrated profibrotic lung microenvironment with inducing profibrotic macrophages. Thus, CB1R in AMs represents a target for anti-fibrotic therapy via pulmonary delivery. PF necessitates multi-targeted therapy to improve therapeutic efficacy. Pulmonary delivery of MRI-1867 (zevaquenabant), a peripherally acting hybrid CB1R/iNOS inhibitor, at 0.5 mg/kg/day is as effective as systemic delivery of 10 mg/kg/day, and nintedanib in mitigating bleomycin-induced PF. Systems pharmacology approach revealed that MRI-1867 and nintedanib treatments reversed alterations in distinct and shared multiple PF-related pathways, which are conserved in human and mouse. Moreover, zevaquenabant treatment also attenuated fibrosis and fibroproliferative mediators in human precision-cut lung slices. Therefore, pulmonary delivery of zevaquenabant provides a more targeted, tolerable and safer therapeutic modality in PF by simultaneously targeting CB1R and iNOS in local fibrotic microenvironment.
2025-06-06 | GSE273132 | GEO
Project description:This series represents samples of multiple myeloma patients with bone lytic lesion by MRI. Keywords = multiple myeloma Keywords = osteolytic lesions Keywords = MRI Keywords = osteoblast Keywords = mesenchymal stem cell Keywords = Wnt signaling Keywords = DKK1 Keywords: other
2004-01-01 | GSE754 | GEO
Project description:This series represents samples of multiple myeloma patients without bone lytic lesion by MRI. Keywords = multiple myeloma Keywords = osteolytic lesions Keywords = MRI Keywords = osteoblast Keywords = mesenchymal stem cell Keywords = Wnt signaling Keywords = DKK1 Keywords: other
2004-01-01 | GSE753 | GEO
Project description:Bacillus pacificus strain:MRI-7 | isolate:MRI-7 Genome sequencing
| PRJNA1214559 | ENA
Project description:This series represents samples of multiple myeloma patients with and without bone lytic lesion by MRI. Keywords = multiple myeloma Keywords = osteolytic lesions Keywords = MRI Keywords = osteoblast Keywords = mesenchymal stem cell Keywords = Wnt signaling Keywords = DKK1 Keywords: other
2004-01-01 | GSE755 | GEO
Project description:Facioscapulohumeral muscular dystrophy (FSHD) is a common, dominantly inherited disease caused by the epigenetic de-repression of the DUX4 gene, a transcription factor normally repressed in somatic cells. As targeted therapies are now possible in FSHD, a better understanding of the relationship between DUX4 activity, muscle pathology and muscle MRI changes are crucial both to understand disease mechanisms and for the design of future clinical trials. Here, we performed MRIs of the lower extremities in 36 individuals with FSHD, followed by needle muscle biopsies in safely accessible muscles. We examined the correlation between MRI characteristics, muscle pathology, and expression of DUX4 target genes. Results show that the presence of elevated MRI STIR signal has substantial predictive value in identifying muscles with active disease and DUX4 target gene expression. In addition, DUX4 target gene expression was detected only in FSHD-affected muscles and not in control muscles, and higher levels of DUX4 target expression was associated with more advanced muscle pathology. These results support the use of MRI to identify FSHD muscles with active disease as measured by histopathology and DUX4 target gene expression and might be useful for the design of studies of disease progression and response to intervention.
2018-09-04 | GSE115650 | GEO
Project description:Not all prostate cancers are visible on multiparametric MRI. The biologic basis and clinical implication of MRI visibility are unknown. We sought to identify genes associated with prognosis and MRI visibility.
2018-02-22 | GSE95369 | GEO
Project description:Whole genome sequence of Chlamydia abortus MRI-10/19
| PRJNA700999 | ENA
Project description:BABEL enables cross-modality translation between multi-omic profiles at single-cell resolution
2021-02-16 | GSE166797 | GEO
Project description:Combination therapy with multiple chemotherapeutic agents is the main approach for cancer treatment in the clinic. Polyphenol-based materials are found in our diet, demonstrate good biocompatibility, and prevent numerous diseases. In this study, we encapsulate two drugs in a single polyphenol-based polymer with Fe3+ or Mn2+ ions as the cross-linker for cancer therapy. The combination index of two drugs is an essential parameter to evaluate drug combinations. The amphiphilic polymer poly(ethylene glycol)-block-polydopamine (PEG-PDA) was prepared by RAFT polymerization. The nanoparticles were prepared via self-assembly with Fe3+ or Mn2+ ions. Both doxorubicin (DOX) and simvastatin (SV) were encapsulated in the core of the nanoparticles. The cell viability and combination index were evaluated in vitro. The tumor accumulation of the nanoparticles was investigated by positron-emission tomography (PET) and magnetic resonance (MR) imaging. The as-prepared nanoparticles exhibited high drug loading capacity. The drug loaded nanoparticles could kill cancer cells effectively with a combination index <1. Both PET and MRI revealed that the nanoparticles showed long blood circulation time and high tumor accumulation. The nanoparticles could inhibit tumor inhibition via intravenous injection of nanoparticles. The polyphenol-based nanoplatform may serve as a promising theranostic candidate for clinical application.
| S-EPMC6760993 | biostudies-literature